With the field having eagerly awaited positive safety and clinical data of allogeneic cell therapies showcasing long-term persistence and durability – it became clear now more than ever that the field must assess the impact of donor contribution to the final cell product quality, and overcome the scalability challenges associated with having a small ‘super-donor’ pool.

The Donor Selection & Cell Source Summit was the ultimate platform to explore the latest global regulatory requirements and differences on donor testing, understand the novel genome sequencing data being used to inform donor selection, and forge new partnerships to ease logistical coordination with donation sites to ensure exclusive availability of selected donor pools.

Whether teams were ahead of the curve with an established donor screening program and selection criteria, or were looking to gain deeper insights into this space to flesh out future donor recruitment and management strategy - they got to participate in this industry-defining forum specifically designed to inspire and facilitate the transparent and interactive discussions on how to transform off-the-shelf cell therapies right from the start.